Among the various things Schmidt is wrong about, we can include this exchange:
"Left: That new "great" product was refused admission this last spring here in the US per the FDA.
Schmidt: That's not true."
From Nuskin's own 10-q:
"The United States Food and Drug Administration (the "FDA") recently refused admission of shipments of our Galvanic Spa facial units because the FDA believes it may require clearance as a medical device." http://biz.yahoo.com/e/120807/nus10-q.ht...
I wouldn't take Schmidt's word as gold here ;) Besides, if Schmidt is right that the Chinese revenue was a 1-time event, then revenues are going to be rather disappointing in coming quarters since these "1-time" earnings are getting modeled into perpetuity by analysts. A lose lose for shareholders, either revenues stagnate or they get busted for being an MLM.